Abstract: Arsenic trioxide is a first-line therapeutic drug for acute promyelocytic leukemia, has inhibitory effects on various solid tumor. However, arsenic trioxide has rapid renal clearance rate, without specific tissue distribution, poorly targeted and easy to produce adverse drug reactions including heart, liver, and kidney toxicity, which limited its clinical application in solid tumors. In recent years, plenty of new arsenic trioxide dosage forms have been continuously developed by scientists to improve its efficacy and reduce its adverse reaction, including liposomes, microspheres, nanoparticles, emulsions, suspension, etc. This review summarized the progresses in new dosage forms of arsenic trioxide, in order to provide new insights for the rational development and application of new arsenic trioxide dosage forms.